# OIT and Xolair® (Omalizumab) in Cow's Milk Allergy

> **NCT01157117** · PHASE2 · COMPLETED · sponsor: **Hugh A Sampson, MD** · enrollment: 77 (actual)

## Conditions studied

- Milk Allergy

## Interventions

- **BIOLOGICAL:** Placebo for omalizumab
- **BIOLOGICAL:** Omalizumab
- **DRUG:** Milk powder

## Key facts

- **NCT ID:** NCT01157117
- **Lead sponsor:** Hugh A Sampson, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2015-01
- **Final completion:** 2015-10
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2020-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01157117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01157117, "OIT and Xolair® (Omalizumab) in Cow's Milk Allergy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01157117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*